Korro Bio announces Dr. Ram Aiyar will present at the TD Cowen Health Care Conference on March 3, 2026.
Quiver AI Summary
Korro Bio, Inc., a biopharmaceutical company focused on developing innovative genetic medicines through RNA editing for both rare and common diseases, announced that its CEO, Dr. Ram Aiyar, will present at the TD Cowen 46th Annual Health Care Conference in Boston from March 2 to 4, 2026. Dr. Aiyar is scheduled to speak on March 3 at 11:10 a.m. ET. Korro aims to create a portfolio of differentiated programs that utilize the body's natural RNA editing capabilities, offering precise and transient edits while improving specificity and long-term tolerability compared to traditional DNA editing methods. The company, based in Cambridge, Massachusetts, plans to leverage its proprietary technology and established regulatory pathways to bring its therapies to patients. Investors are encouraged to stay updated via Korro's Investor Relations website and social media platforms.
Potential Positives
- Korro Bio is showcasing its innovative approach to genetic medicines by presenting at a prominent healthcare conference, which can enhance visibility and credibility in the industry.
- The company's focus on RNA editing for addressing both rare and common diseases positions it favorably within the growing field of genetic therapies.
- Dr. Ram Aiyar's participation as a speaker at the conference highlights leadership engagement, potentially attracting investor interest and partnerships.
- Korro's commitment to utilizing established regulatory pathways and proven delivery methods may signal confidence in the feasibility and market readiness of its products.
Potential Negatives
- The press release lacks specific details about Korro Bio's current financial performance or pipeline updates, which may raise concerns among investors about the company's transparency and progress.
- The announcement focuses solely on upcoming presentations, with no mention of recent achievements or upcoming product releases, potentially indicating a lack of significant advancements in their technology.
- Singling out an individual for presentation without broader context might create uncertainty about the company’s leadership and overall direction if stakeholders perceive reliance on one person.
FAQ
What is Korro Bio, Inc. focused on?
Korro Bio, Inc. focuses on developing genetic medicines through RNA editing for both rare and prevalent diseases.
When will Dr. Ram Aiyar present at the TD Cowen Health Care Conference?
Dr. Ram Aiyar will present on March 3, 2026, at 11:10 a.m. ET during the TD Cowen Health Care Conference.
Where is the TD Cowen Health Care Conference being held?
The TD Cowen Health Care Conference is being held at the Boston Marriott Copley Place in Boston, MA.
How does Korro Bio's RNA editing technology work?
Korro's RNA editing technology allows precise single base edits, enhancing the specificity and tolerability of genetic medicines.
What platforms does Korro use for investor communications?
Korro communicates with investors via its Investor Relations website, LinkedIn, and X (Twitter), along with press releases and SEC filings.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KRRO Hedge Fund Activity
We have seen 46 institutional investors add shares of $KRRO stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LYNX1 CAPITAL MANAGEMENT LP added 677,915 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,430,099
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 671,981 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,382,567
- NANTAHALA CAPITAL MANAGEMENT, LLC added 600,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,806,000
- POINT72 ASSET MANAGEMENT, L.P. removed 531,969 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $4,261,071
- FMR LLC removed 525,824 shares (-93.3%) from their portfolio in Q4 2025, for an estimated $4,211,850
- CORMORANT ASSET MANAGEMENT, LP removed 465,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,724,650
- TRI LOCUM PARTNERS LP removed 337,764 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,705,489
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KRRO Analyst Ratings
Wall Street analysts have issued reports on $KRRO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Clear Street issued a "Buy" rating on 02/19/2026
- William Blair issued a "Outperform" rating on 02/17/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/29/2026
- Piper Sandler issued a "Overweight" rating on 01/29/2026
To track analyst ratings and price targets for $KRRO, check out Quiver Quantitative's $KRRO forecast page.
$KRRO Price Targets
Multiple analysts have issued price targets for $KRRO recently. We have seen 7 analysts offer price targets for $KRRO in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Bill Maughan from Clear Street set a target price of $18.0 on 02/19/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $20.0 on 01/29/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $30.0 on 01/29/2026
- Keay Nakae from Chardan Capital set a target price of $15.0 on 01/29/2026
- Kostas Biliouris from Oppenheimer set a target price of $22.0 on 01/28/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $21.0 on 01/28/2026
- Luca Issi from RBC Capital set a target price of $8.0 on 11/13/2025
Full Release
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46 th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2 nd – 4 th , 2026. Dr. Aiyar’s presentation will take place on Tuesday, March 3, 2026, at 11:10 a.m. ET.
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Korro Bio Contact Information
Investor & Media Contact
[email protected]
.jpeg)
